As of June 9, 2020,
a U.S. patent (10/675,294) for a pharmaceutical composition for the treatment of corneal damage containing 8-oxo-2'-deoxyguanosine or a pharmaceutically acceptable salt thereof as an active ingredient
has been registered, and we are pleased to announce this achievement. Based on this patent, RudaCure is simultaneously pursuing U.S. clinical trials and preparing for its U.S. market entry.